Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China

NCT03575065 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT03575065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03575065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
June 22, 2018
Completion date
April 14, 2021
Enrollment
88 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer